Amendment to Schedule 13D Filing for Theravance Biopharma, Inc.

This filing is an amendment (Amendment No. 3) to a Schedule 13D, originally filed on April 12, 2023, concerning Theravance Biopharma, Inc. The amendment restates Item 5 of the Schedule 13D. The percentages of shares held are based on 51,492,924 shares outstanding as of February 28, 2026. Weiss Asset Management LP, along with affiliated entities and Andrew M. Weiss, collectively hold a significant number of shares. Specifically, 4,628,074 shares (9.0%) are held by BIP, managed by Weiss Asset Management LP, with voting and disposal power held by Dr. Weiss. Additionally, 2,828,986 shares (5.5%) are held by BGO, also managed by Weiss Asset Management LP, with similar control attributed to Dr. Weiss. The reporting persons disclaim beneficial ownership beyond their pecuniary interest. This amendment does not reflect any transactions in the past 60 days.